MX384392B - Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. - Google Patents

Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.

Info

Publication number
MX384392B
MX384392B MX2016008841A MX2016008841A MX384392B MX 384392 B MX384392 B MX 384392B MX 2016008841 A MX2016008841 A MX 2016008841A MX 2016008841 A MX2016008841 A MX 2016008841A MX 384392 B MX384392 B MX 384392B
Authority
MX
Mexico
Prior art keywords
lipid synthesis
viral infections
against cancer
use against
heterocyclic modulators
Prior art date
Application number
MX2016008841A
Other languages
English (en)
Other versions
MX2016008841A (es
Inventor
Allan S Wagman
Cristiana A Zaharia
Greg Duke
Haiying Cai
Lily W Hu
' FARRELL Marie O
Russell J Johnson
Timothy Heuer
Yamini Ohol-Gupta
Original Assignee
Sagimet Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagimet Biosciences Inc filed Critical Sagimet Biosciences Inc
Publication of MX2016008841A publication Critical patent/MX2016008841A/es
Publication of MX384392B publication Critical patent/MX384392B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan moduladores heterocíclicos de la síntesis de lípidos, así como también sales aceptables para uso farmacéutico de los mismos; también composiciones farmacéuticas que comprenden tales compuestos; y métodos de tratamiento de afecciones caracterizadas por la desregulación de una vía de ácido graso sintasa por medio de la administración de tales compuestos. (ver Fórmula).
MX2016008841A 2014-01-07 2015-01-07 Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. MX384392B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461924520P 2014-01-07 2014-01-07
PCT/US2015/010459 WO2015105860A1 (en) 2014-01-07 2015-01-07 Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

Publications (2)

Publication Number Publication Date
MX2016008841A MX2016008841A (es) 2016-10-13
MX384392B true MX384392B (es) 2025-03-14

Family

ID=52394405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008841A MX384392B (es) 2014-01-07 2015-01-07 Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.

Country Status (16)

Country Link
US (1) US9994550B2 (es)
EP (1) EP3092232B1 (es)
JP (1) JP6522007B2 (es)
KR (1) KR102335142B1 (es)
CN (1) CN105980376B (es)
AU (1) AU2015204907B2 (es)
BR (1) BR112016015879B1 (es)
CA (1) CA2935767C (es)
ES (1) ES2913858T3 (es)
IL (1) IL246463B (es)
MX (1) MX384392B (es)
NZ (1) NZ721780A (es)
RU (1) RU2766087C2 (es)
SG (1) SG11201605422TA (es)
WO (1) WO2015105860A1 (es)
ZA (1) ZA201604560B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170119786A1 (en) 2011-03-08 2017-05-04 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
NZ729443A (en) 2012-07-03 2017-11-24 3-V Biosciences Inc Heterocyclic modulators of lipid synthesis
JP6691909B2 (ja) 2014-08-15 2020-05-13 サギメット バイオサイエンシーズ インコーポレイテッド 薬物耐性癌の治療で用いるための脂肪酸シンターゼ阻害剤
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
WO2018089904A1 (en) * 2016-11-11 2018-05-17 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
CN110366562A (zh) * 2016-12-12 2019-10-22 豪夫迈·罗氏有限公司 使用抗pd-l1抗体和抗雄激素治疗癌症的方法
CN106562961B (zh) * 2016-12-12 2017-09-01 深圳市宏辉浩医药科技有限公司 一种治疗脑梗塞的药物组合物
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
WO2025086054A1 (zh) * 2023-10-23 2025-05-01 歌礼生物科技（杭州）有限公司 一种包含苯甲腈衍生物的药物组合物
WO2025120168A1 (en) 2023-12-07 2025-06-12 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement (Inrae) Sulfonamide derivatives and use thereof in the treatment of cryptosporidium infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
RU2419612C2 (ru) * 2003-12-23 2011-05-27 Астекс Терапьютикс Лимитед Производные пиразола в качестве модуляторов протеинкиназы
WO2008075077A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Piperidine derivatives for the treatment of obesity
TW200833663A (en) * 2006-12-21 2008-08-16 Astrazeneca Ab Therapeutic agents
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
AR086837A1 (es) * 2011-03-08 2014-01-29 3 V Biosciences Inc Moduladores heterociclicos de sintesis lipidica
WO2012122391A1 (en) 2011-03-08 2012-09-13 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
NZ729443A (en) * 2012-07-03 2017-11-24 3-V Biosciences Inc Heterocyclic modulators of lipid synthesis

Also Published As

Publication number Publication date
US9994550B2 (en) 2018-06-12
CN105980376B (zh) 2019-03-22
BR112016015879A2 (es) 2017-08-08
KR102335142B1 (ko) 2021-12-06
RU2766087C2 (ru) 2022-02-07
AU2015204907A1 (en) 2016-07-21
ES2913858T3 (es) 2022-06-06
RU2016127634A3 (es) 2019-06-17
ZA201604560B (en) 2019-01-30
JP6522007B2 (ja) 2019-05-29
MX2016008841A (es) 2016-10-13
JP2017502083A (ja) 2017-01-19
BR112016015879B1 (pt) 2022-06-14
CA2935767A1 (en) 2015-07-16
EP3092232B1 (en) 2022-03-09
CN105980376A (zh) 2016-09-28
EP3092232A1 (en) 2016-11-16
RU2016127634A (ru) 2018-02-09
IL246463A0 (en) 2016-08-31
AU2015204907B2 (en) 2018-08-02
NZ721780A (en) 2022-01-28
US20160326141A1 (en) 2016-11-10
WO2015105860A9 (en) 2016-02-04
IL246463B (en) 2022-04-01
WO2015105860A1 (en) 2015-07-16
SG11201605422TA (en) 2016-07-28
CA2935767C (en) 2023-01-31
KR20160105416A (ko) 2016-09-06

Similar Documents

Publication Publication Date Title
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
NZ703162A (en) Heterocyclic modulators of lipid synthesis
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
ECSP17069696A (es) Compuestos novedosos
EA201500931A1 (ru) Производные пиридин-4-ила
CR20160527A (es) Derivados de carboxamida
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY36123A (es) Derivados de carboxamida